{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T05:19:01Z","timestamp":1790659141525,"version":"4.1.0"},"reference-count":76,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,1]],"date-time":"2018-05-01T00:00:00Z","timestamp":1525132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":1662,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2018,5]]},"DOI":"10.1111\/ajt.14731","type":"journal-article","created":{"date-parts":[[2018,3,9]],"date-time":"2018-03-09T22:52:40Z","timestamp":1520635960000},"page":"1046-1058","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Plasma cell diseases and organ transplant: A comprehensive review"],"prefix":"10.1016","volume":"18","author":[{"given":"Andrew J.","family":"Cowan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher K.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward N.","family":"Libby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1111\/ajt.14731_bib1","unstructured":"OCEBM Levels of Evidence Working Group. The Oxford Levels of Evidence 2. Oxford Centre for Evidence-Based Medicine. https:\/\/www.cebm.net\/index.aspx?o=5653"},{"issue":"7","key":"10.1111\/ajt.14731_bib2","first-page":"578","article-title":"Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM)","volume":"25","author":"Kyle","year":"2011","journal-title":"Oncology (Williston Park)."},{"issue":"13","key":"10.1111\/ajt.14731_bib3","doi-asserted-by":"crossref","first-page":"1362","DOI":"10.1056\/NEJMoa054494","article-title":"Prevalence of monoclonal gammopathy of undetermined significance","volume":"354","author":"Kyle","year":"2006","journal-title":"N Engl J Med."},{"issue":"8","key":"10.1111\/ajt.14731_bib4","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1056\/NEJMoa01133202","article-title":"A long-term study of prognosis in monoclonal gammopathy of undetermined significance","volume":"346","author":"Kyle","year":"2002","journal-title":"N Engl J Med."},{"issue":"3","key":"10.1111\/ajt.14731_bib5","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","article-title":"Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance","volume":"106","author":"Rajkumar","year":"2005","journal-title":"Blood."},{"issue":"6","key":"10.1111\/ajt.14731_bib6","doi-asserted-by":"crossref","first-page":"984","DOI":"10.3324\/haematol.2013.100552","article-title":"The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European myeloma network","volume":"99","author":"van de Donk","year":"2014","journal-title":"Haematologica."},{"issue":"1","key":"10.1111\/ajt.14731_bib7","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.transproceed.2014.11.021","article-title":"Follow-up monoclonal gammopathy of undetermined significance in kidney transplant","volume":"47","author":"Cuellar-Garcia","year":"2015","journal-title":"Transpl Proc."},{"issue":"9","key":"10.1111\/ajt.14731_bib8","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1111\/ctr.12595","article-title":"Neoplastic and non-neoplastic complications of solid organ transplantation in patients with preexisting monoclonal gammopathy of undetermined significance","volume":"29","author":"Goebel","year":"2015","journal-title":"Clin Transplant."},{"issue":"5","key":"10.1111\/ajt.14731_bib9","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/TP.0b013e318225db2c","article-title":"Monoclonal gammopathy of undetermined significance does not affect outcomes in patients undergoing solid organ transplants","volume":"92","author":"Jimenez-Zepeda","year":"2011","journal-title":"Transplantation."},{"issue":"7","key":"10.1111\/ajt.14731_bib10","doi-asserted-by":"crossref","first-page":"a015677","DOI":"10.1101\/cshperspect.a015677","article-title":"Cancer in the transplant recipient","volume":"3","author":"Chapman","year":"2013","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"4","key":"10.1111\/ajt.14731_bib11","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1159\/000337482","article-title":"Long-term follow-up of patients with monoclonal gammopathy of undetermined significance after kidney transplantation","volume":"35","author":"Naina","year":"2012","journal-title":"Am J Nephrol."},{"issue":"2","key":"10.1111\/ajt.14731_bib12","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1111\/j.1399-0012.2011.01539.x","article-title":"Initial survival data of kidney transplant patients with pre-transplant monoclonal gammopathy","volume":"26","author":"Soltero","year":"2012","journal-title":"Clin Transplant."},{"issue":"8","key":"10.1111\/ajt.14731_bib13","doi-asserted-by":"crossref","first-page":"2344","DOI":"10.1016\/j.transproceed.2015.08.023","article-title":"Outcomes of monoclonal gammopathy of undetermined significance in patients who underwent kidney transplantation","volume":"47","author":"Bancu","year":"2015","journal-title":"Transpl Proc."},{"issue":"1\u20132","key":"10.1111\/ajt.14731_bib14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1016\/S0041-1345(00)02602-6","article-title":"Monoclonal gammopathy in heart transplantation: risk factor analysis and relevance of immunosuppressive load","volume":"33","author":"Caforio","year":"2001","journal-title":"Transpl Proc."},{"issue":"5","key":"10.1111\/ajt.14731_bib15","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.V98.5.1332","article-title":"Detection of gammopathy by serum protein electrophoresis for predicting and managing therapy of lymphoproliferative disorder in 911 recipients of liver transplants","volume":"98","author":"Lemoine","year":"2001","journal-title":"Blood."},{"issue":"5","key":"10.1111\/ajt.14731_bib16","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1002\/lt.500020508","article-title":"Development of monoclonal gammopathy precedes the development of Epstein-Barr virus-induced posttransplant lymphoproliferative disorder","volume":"2","author":"Badley","year":"1996","journal-title":"Liver Transpl Surg."},{"issue":"9","key":"10.1111\/ajt.14731_bib17","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1097\/00007890-200211150-00025","article-title":"Living kidney donors in need of kidney transplants: a report from the organ procurement and transplantation network","volume":"74","author":"Ellison","year":"2002","journal-title":"Transplantation."},{"issue":"10","key":"10.1111\/ajt.14731_bib18","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1038\/ki.2009.20","article-title":"Global trends in the rates of living kidney donation","volume":"75","author":"Horvat","year":"2009","journal-title":"Kidney Int."},{"issue":"6 suppl","key":"10.1111\/ajt.14731_bib19","first-page":"S53","article-title":"A report of the amsterdam forum on the care of the live kidney donor: data and medical guidelines","volume":"79","author":"Delmonico","year":"2005","journal-title":"Transplantation."},{"issue":"4","key":"10.1111\/ajt.14731_bib20","first-page":"256","article-title":"Monoclonal gammopathy of undetermined significance: a contraindication for living kidney donation?","volume":"4","author":"Serra","year":"2011","journal-title":"NDT Plus."},{"issue":"9","key":"10.1111\/ajt.14731_bib21","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1111\/ajt.13804","article-title":"Donor monoclonal gammopathy may cause lymphoproliferative disorders in solid organ transplant recipients","volume":"16","author":"Felldin","year":"2016","journal-title":"Am J Transplant."},{"issue":"3","key":"10.1111\/ajt.14731_bib22","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1046\/j.1365-2141.2000.01913.x","article-title":"IgA myeloma of donor origin arising 7 years after allogeneic renal transplant","volume":"108","author":"Grey","year":"2000","journal-title":"Br J Haematol."},{"issue":"2","key":"10.1111\/ajt.14731_bib23","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1111\/j.1600-6143.2005.01170.x","article-title":"Postrenal transplant non-EBV multiple myeloma of donor origin","volume":"6","author":"Peri","year":"2006","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14731_bib24","first-page":"7","article-title":"Cancer statistics, 2016","volume":"66","author":"Siegel","year":"2016","journal-title":"CA Cancer J Clin."},{"issue":"9","key":"10.1111\/ajt.14731_bib25","doi-asserted-by":"crossref","first-page":"1915","DOI":"10.1038\/leu.2016.380","article-title":"Trends in overall survival and costs of multiple myeloma, 2000-2014","volume":"31","author":"Fonseca","year":"2017","journal-title":"Leukemia."},{"issue":"12","key":"10.1111\/ajt.14731_bib26","doi-asserted-by":"crossref","first-page":"e538","DOI":"10.1016\/S1470-2045(14)70442-5","article-title":"International myeloma working group updated criteria for the diagnosis of multiple myeloma","volume":"15","author":"Rajkumar","year":"2014","journal-title":"Lancet Oncol."},{"issue":"7","key":"10.1111\/ajt.14731_bib27","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1002\/ajh.24402","article-title":"Multiple myeloma: 2016 update on diagnosis, risk-stratification, and management","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Am J Hematol."},{"issue":"12","key":"10.1111\/ajt.14731_bib28","doi-asserted-by":"crossref","first-page":"2477","DOI":"10.1200\/JCO.2004.10.127","article-title":"Thalidomid: current role in the treatment of non-plasma cell malignancies","volume":"22","author":"Kumar","year":"2004","journal-title":"J Clin Oncol."},{"issue":"5","key":"10.1111\/ajt.14731_bib29","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar","year":"2008","journal-title":"Blood."},{"issue":"5","key":"10.1111\/ajt.14731_bib30","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/8466","article-title":"Free radical-mediated oxidative DNA damage in the mechanism of thalidomide teratogenicity","volume":"5","author":"Parman","year":"1999","journal-title":"Nat Med."},{"key":"10.1111\/ajt.14731_bib31","doi-asserted-by":"crossref","first-page":"172458","DOI":"10.1155\/2015\/172458","article-title":"Mechanism of action of bortezomib and the new proteasome inhibitors on myeloma cells and the bone microenvironment: impact on myeloma-induced alterations of bone remodeling","volume":"2015","author":"Accardi","year":"2015","journal-title":"Biomed Res Int."},{"issue":"19","key":"10.1111\/ajt.14731_bib32","doi-asserted-by":"crossref","first-page":"1770","DOI":"10.1056\/NEJMoa1114083","article-title":"Lenalidomide after stem-cell transplantation for multiple myeloma","volume":"366","author":"McCarthy","year":"2012","journal-title":"N Engl J Med."},{"issue":"24","key":"10.1111\/ajt.14731_bib33","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J Clin Oncol."},{"issue":"3","key":"10.1111\/ajt.14731_bib34","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1046\/j.1523-1755.2003.00813.x","article-title":"High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease","volume":"63","author":"Casserly","year":"2003","journal-title":"Kidney Int."},{"issue":"7","key":"10.1111\/ajt.14731_bib35","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1182\/bloodadvances.2016003905","article-title":"Network meta-analysis of randomized trials in multiple myeloma: efficacy and safety in relapsed\/refractory patients","volume":"1","author":"Botta","year":"2017","journal-title":"Blood Adv."},{"issue":"9","key":"10.1111\/ajt.14731_bib36","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.4103\/0366-6999.156134","article-title":"Efficacy and safety of lenalidomide in the treatment of multiple myeloma: a systematic review and meta-analysis of randomized controlled trials","volume":"128","author":"Qiao","year":"2015","journal-title":"Chin Med J."},{"issue":"13","key":"10.1111\/ajt.14731_bib37","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1200\/JCO.2015.65.0044","article-title":"International myeloma working group recommendations for the diagnosis and management of myeloma-related renal impairment","volume":"34","author":"Dimopoulos","year":"2016","journal-title":"J Clin Oncol."},{"issue":"1","key":"10.1111\/ajt.14731_bib38","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1093\/annonc\/mdt483","article-title":"Significant improvement in the survival of patients with multiple myeloma presenting with severe renal impairment after the introduction of novel agents","volume":"25","author":"Dimopoulos","year":"2014","journal-title":"Ann Oncol."},{"issue":"3","key":"10.1111\/ajt.14731_bib39","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1038\/bmt.2012.111","article-title":"Renal allografts in plasma cell myeloma hematopoietic cell graft recipients: on the verge of an explosion?","volume":"48","author":"Nayak","year":"2013","journal-title":"Bone Marrow Transplant."},{"issue":"26","key":"10.1111\/ajt.14731_bib40","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: a report from international myeloma working group","volume":"33","author":"Palumbo","year":"2015","journal-title":"J Clin Oncol."},{"issue":"6","key":"10.1111\/ajt.14731_bib41","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1111\/ajt.12234","article-title":"Plasma cell neoplasms in US solid organ transplant recipients","volume":"13","author":"Engels","year":"2013","journal-title":"Am J Transplant."},{"issue":"9581","key":"10.1111\/ajt.14731_bib42","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet (London, England)."},{"issue":"8","key":"10.1111\/ajt.14731_bib43","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/j.1600-6143.2010.03181.x","article-title":"Comparison of the incidence of malignancy in recipients of different types of organ: a UK Registry audit","volume":"10","author":"Collett","year":"2010","journal-title":"Am J Transplant."},{"issue":"1","key":"10.1111\/ajt.14731_bib44","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1111\/ctr.12482","article-title":"Multiple myeloma after kidney transplantation","volume":"29","author":"Safadi","year":"2015","journal-title":"Clin Transplant."},{"issue":"22","key":"10.1111\/ajt.14731_bib45","doi-asserted-by":"crossref","first-page":"3583","DOI":"10.1182\/blood-2013-05-495929","article-title":"How I treat monoclonal gammopathy of renal significance (MGRS)","volume":"122","author":"Fermand","year":"2013","journal-title":"Blood."},{"issue":"11","key":"10.1111\/ajt.14731_bib46","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1002\/ajh.24528","article-title":"Outcomes of patients with renal monoclonal immunoglobulin deposition disease","volume":"91","author":"Kourelis","year":"2016","journal-title":"Am J Hematol."},{"issue":"2","key":"10.1111\/ajt.14731_bib47","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/j.1523-1755.2004.00427.x","article-title":"High dose chemotherapy in light chain or light and heavy chain deposition disease","volume":"65","author":"Royer","year":"2004","journal-title":"Kidney Int."},{"issue":"6","key":"10.1111\/ajt.14731_bib48","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1093\/ndt\/gfm918","article-title":"Long-term outcome of autologous stem cell transplantation in light chain deposition disease","volume":"23","author":"Lorenz","year":"2008","journal-title":"Nephrol Dial Transplant."},{"issue":"1","key":"10.1111\/ajt.14731_bib49","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1053\/j.ajkd.2003.09.020","article-title":"Long-term outcome of renal transplantation in light-chain deposition disease","volume":"43","author":"Leung","year":"2004","journal-title":"Am J Kidney Dis."},{"issue":"26","key":"10.1111\/ajt.14731_bib50","doi-asserted-by":"crossref","first-page":"2805","DOI":"10.1182\/blood-2015-07-658872","article-title":"Natural history and outcome of light chain deposition disease","volume":"126","author":"Sayed","year":"2015","journal-title":"Blood."},{"issue":"4","key":"10.1111\/ajt.14731_bib51","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/00005792-200107000-00004","article-title":"Cryoglobulinemia: study of etiologic factors and clinical and immunologic features in 443 patients from a single center","volume":"80","author":"Trejo","year":"2001","journal-title":"Medicine."},{"issue":"4","key":"10.1111\/ajt.14731_bib52","doi-asserted-by":"crossref","first-page":"767","DOI":"10.3109\/10428194.2012.671481","article-title":"Type I cryoglobulinemia in multiple myeloma, a rare entity: analysis of clinical and biological characteristics of seven cases and review of the literature","volume":"54","author":"Payet","year":"2013","journal-title":"Leuk Lymphoma."},{"issue":"7","key":"10.1111\/ajt.14731_bib53","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1002\/ajh.24745","article-title":"Clinical presentation and outcomes of patients with type 1 monoclonal cryoglobulinemia","volume":"92","author":"Sidana","year":"2017","journal-title":"Am J Hematol."},{"issue":"10","key":"10.1111\/ajt.14731_bib54","doi-asserted-by":"crossref","first-page":"4273","DOI":"10.1016\/j.transproceed.2005.11.020","article-title":"Cryoglobulinemia in kidney transplant recipients","volume":"37","author":"Sens","year":"2005","journal-title":"Transpl Proc."},{"issue":"8","key":"10.1111\/ajt.14731_bib55","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/nrneph.2010.85","article-title":"C3 glomerulopathy: a new classification","volume":"6","author":"Fakhouri","year":"2010","journal-title":"Nat Rev Nephrol."},{"issue":"3","key":"10.1111\/ajt.14731_bib56","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1136\/jmg.2006.045328","article-title":"Primary glomerulonephritis with isolated C3 deposits: a new entity which shares common genetic risk factors with haemolytic uraemic syndrome","volume":"44","author":"Servais","year":"2007","journal-title":"J Med Genet."},{"issue":"11","key":"10.1111\/ajt.14731_bib57","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1182\/blood-2016-08-737163","article-title":"Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy","volume":"129","author":"Chauvet","year":"2017","journal-title":"Blood."},{"key":"10.1111\/ajt.14731_bib58","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"Al amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis."},{"issue":"15","key":"10.1111\/ajt.14731_bib59","doi-asserted-by":"crossref","first-page":"3147","DOI":"10.1182\/blood-2009-04-202879","article-title":"How I treat amyloidosis","volume":"114","author":"Comenzo","year":"2009","journal-title":"Blood."},{"issue":"16","key":"10.1111\/ajt.14731_bib60","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1182\/blood-2011-01-330738","article-title":"Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients","volume":"118","author":"Cibeira","year":"2011","journal-title":"Blood."},{"issue":"19","key":"10.1111\/ajt.14731_bib61","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","article-title":"Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis","volume":"119","author":"Mikhael","year":"2012","journal-title":"Blood."},{"issue":"1","key":"10.1111\/ajt.14731_bib62","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1111\/bjh.13656","article-title":"Disease-free survival following high dose or standard dose therapy in patients with amyloidosis","volume":"174","author":"Kiel","year":"2016","journal-title":"Br J Haematol."},{"issue":"7","key":"10.1111\/ajt.14731_bib63","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood-2017-01-763599","article-title":"Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis","volume":"130","author":"Kaufman","year":"2017","journal-title":"Blood."},{"issue":"15","key":"10.1111\/ajt.14731_bib64","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1182\/blood-2016-12-756528","article-title":"A phase 2 trial of pomalidomide and dexamethasone rescue treatment in patients with AL amyloidosis","volume":"129","author":"Palladini","year":"2017","journal-title":"Blood."},{"issue":"8","key":"10.1111\/ajt.14731_bib65","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1182\/blood-2016-04-710822","article-title":"Pomalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 1 and 2 trial","volume":"128","author":"Sanchorawala","year":"2016","journal-title":"Blood."},{"issue":"2","key":"10.1111\/ajt.14731_bib66","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood-2006-07-030544","article-title":"Lenalidomide and dexamethasone in the treatment of AL amyloidosis: results of a phase 2 trial","volume":"109","author":"Sanchorawala","year":"2007","journal-title":"Blood."},{"issue":"8","key":"10.1111\/ajt.14731_bib67","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.healun.2008.05.016","article-title":"Autologous stem cell transplant after heart transplant for light chain (Al) amyloid cardiomyopathy","volume":"27","author":"Lacy","year":"2008","journal-title":"J Heart Lung Transplant."},{"issue":"1","key":"10.1111\/ajt.14731_bib68","first-page":"45","article-title":"Primary systemic amyloidosis: clinical and laboratory features in 474 cases","volume":"32","author":"Kyle","year":"1995","journal-title":"Semin Hematol."},{"issue":"10","key":"10.1111\/ajt.14731_bib69","doi-asserted-by":"crossref","first-page":"3132","DOI":"10.1093\/ndt\/gfp201","article-title":"Clinical outcome of immunoglobulin light chain amyloidosis affecting the kidney","volume":"24","author":"Gertz","year":"2009","journal-title":"Nephrol Dial Transplant."},{"issue":"7","key":"10.1111\/ajt.14731_bib70","doi-asserted-by":"crossref","first-page":"1660","DOI":"10.1111\/j.1600-6143.2005.00920.x","article-title":"Living donor kidney and autologous stem cell transplantation for primary systemic amyloidosis (AL) with predominant renal involvement","volume":"5","author":"Leung","year":"2005","journal-title":"Am J Transplant."},{"issue":"6","key":"10.1111\/ajt.14731_bib71","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/ndt\/gfr067","article-title":"Long-term outcomes of patients with light chain amyloidosis (AL) after renal transplantation with or without stem cell transplantation","volume":"26","author":"Herrmann","year":"2011","journal-title":"Nephrol Dial Transplant."},{"issue":"9","key":"10.1111\/ajt.14731_bib72","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1111\/j.1600-6143.2010.03227.x","article-title":"Solid organ transplantation in AL amyloidosis","volume":"10","author":"Sattianayagam","year":"2010","journal-title":"Am J Transplant."},{"issue":"2","key":"10.1111\/ajt.14731_bib73","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s10741-014-9464-5","article-title":"Natural history and therapy of AL cardiac amyloidosis","volume":"20","author":"Grogan","year":"2015","journal-title":"Heart Fail Rev."},{"issue":"2","key":"10.1111\/ajt.14731_bib74","doi-asserted-by":"crossref","first-page":"380","DOI":"10.5500\/wjt.v6.i2.380","article-title":"Long term outcomes of cardiac transplant for immunoglobulin light chain amyloidosis: the Mayo Clinic experience","volume":"6","author":"Grogan","year":"2016","journal-title":"World J Transplant."},{"issue":"8","key":"10.1111\/ajt.14731_bib75","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1097\/TP.0b013e3181f10edb","article-title":"Cardiac transplantation followed by dose-intensive melphalan and autologous stem-cell transplantation for light chain amyloidosis and heart failure","volume":"90","author":"Dey","year":"2010","journal-title":"Transplantation."},{"issue":"9","key":"10.1111\/ajt.14731_bib76","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/j.acvd.2008.06.018","article-title":"Heart transplantation in systemic (AL) amyloidosis: a retrospective study of eight French patients","volume":"101","author":"Mignot","year":"2008","journal-title":"Arch Cardiovasc Dis."}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fajt.14731","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522095235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522095235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/ajt.14731\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T05:21:32Z","timestamp":1761628892000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522095235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5]]},"references-count":76,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2018,5]]}},"alternative-id":["S1600613522095235"],"URL":"https:\/\/doi.org\/10.1111\/ajt.14731","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Plasma cell diseases and organ transplant: A comprehensive review","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/ajt.14731","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2018 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}